Related Experiment Videos
[In vitro sensitivity of Vibrio cholerae serotype 0:139 to an intestinal antiseptic tiliquinol-tilbroquinol
Abstract:
O:139 is a new serotype of Vibrio cholerae that is not agglutinated by an O:1 antiserum but causes epidemics of cholera. Strains of O:139 serotype are resistant to O/129 compound and many antibiotics but are sensitive to tetracyclines and tiliquinol-tilbroquinol (Intétrix). The clinical management of the patients infected with serotype O:139 is identical to that of usual choleric patients. However, the immunological difference with O:1 serotype must lead to reconsider both the diagnosis and the vaccinating strategies of cholera.
Insights
A new Vibrio cholerae serotype, O:139, causes cholera epidemics and is resistant to many antibiotics. Diagnosis and cholera vaccination strategies must be reconsidered due to its immunological difference from O:1 serotypes.
Area of Science:
- Microbiology
- Infectious Diseases
- Epidemiology
Background:
- Vibrio cholerae causes cholera, a significant global health concern.
- Cholera outbreaks are typically associated with O:1 serotypes.
- Emergence of new serotypes can impact disease control strategies.
Purpose of the Study:
- To characterize the newly identified O:139 serotype of Vibrio cholerae.
- To assess the antimicrobial susceptibility of O:139 strains.
- To evaluate the implications of O:139 for cholera diagnosis and prevention.
Main Methods:
- Serological testing using O:1 antiserum.
- Antimicrobial susceptibility testing against various antibiotics and compounds.
- Clinical observation of patients infected with O:139.
Main Results:
- O:139 Vibrio cholerae strains were identified, distinct from O:1 serotypes.
- These strains exhibit resistance to O/129 compound and numerous antibiotics.
- Sensitivity was observed towards tetracyclines and tiliquinol-tilbroquinol (Intetrix).
- Clinical management for O:139 infections is similar to conventional cholera cases.
Conclusions:
- The O:139 serotype represents a new epidemic threat of cholera.
- Antibiotic resistance patterns necessitate tailored treatment approaches.
- Immunological differences require re-evaluation of current cholera diagnostic and vaccination strategies.